Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.
Journal: Clinical ophthalmology (Auckland, N.Z.)
Published: September 27, 2023
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
Journal: International journal of retina and vitreous
Published: October 17, 2022
Showing 1-2 of 2
Last Updated: 09/26/2026